ArticleScientific reports2024
Tumefactive demyelinating lesions: a retrospective cohort study in Thailand.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Biopsy-proven tumefactive demyelinating lesions: a systematic review and meta-analysis.BMC neurology · 2026Pooled it
- Tumefactive Multiple Sclerosis Mimicking a High-Grade Glioma: A Case Report and Literature Review.Reports (MDPI) · 2026Article
- Article
- Non-Syndromic Tumefactive Demyelinating Lesions in the Pediatric Population: Four Case Reports and Review of the Literature.Annals of the Child Neurology Society · 2026Article
- Cerebral tumefactive demyelinating lesions: clinical spectrum, long-term outcomes, and treatment.Acta neurologica Belgica · 2026Article
- Challenges in the Diagnosis of Multiple Sclerosis: A Case Report.Acta medica Lituanica · 2026Article
- Tumefactive Demyelinating Lesion Mimicking Low-Grade Astrocytoma with a T2/FLAIR Mismatch Sign: A Case Report and Review of the Literature.Diagnostics (Basel, Switzerland) · 2025Article
- Tumefactive demyelinating lesions: a case report and literature review.BMC neurology · 2025Review
- Hyperperfusion Improvement: A Potential Therapeutic Marker in Neuromyelitis Optica Spectrum Disorder (NMOSD).Diagnostics (Basel, Switzerland) · 2025Article
- Tumefactive Demyelinating Lesion Induced by Infliximab in a Patient With Rheumatoid Arthritis: A Case Report.Clinical case reports · 2025Article
- Overtime Challenges of Diagnosis and Treatment in Two Pediatric Patients with Extensive Cerebral Tumefactive Lesions Indicative of Baló's Type Multiple Sclerosis.Children (Basel, Switzerland) · 2025Article
- Identifying Tumefactive Demyelination on Synthetic MRI Myelin Maps.Case reports in radiology · 2025Article
- Subgroup analysis of tumefactive demyelinating lesions: clinical, imaging features and outcomes.BMJ neurology open · 2025Article
- Fingolimod-associated Balo's concentric sclerosis in multiple sclerosis: A case report.Clinical case reports · 2024Article
- Article
- Tumefactive demyelinating lesions: A literature review of recent findings.Neurosciences (Riyadh, Saudi Arabia) · 2024Review
- Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumefactive demyelinating lesions (TDL), characterized by large (≥ 2 cm) demyelinating lesions mimicking tumors, are a rare manifestation of the central nervous system inflammatory demyelinating diseases (CNS-IDD). Distinguishing TDL from other brain lesions can be challenging, often necessitating biopsy or advanced diagnostics. The natural history of TDL varies among races. This study aimed to assess demographics, clinical and radiological features, laboratory findings, management, and outcomes of Thai patients with TDL. We retrospectively reviewed records of twenty-six patients with TDL from the Multiple Sclerosis and Related Disorders registry from two tertiary medical centers. Among 1102 CNS-IDD patients, 26 (2.4%) had TDL. The median age at TDLs onset was 34.5 years (range 17-75); 69.2% were female. Over 70% manifested TDL as their initial CNS-IDD presentation. Common presenting symptoms included motor deficits, sensory disturbances, and cognitive problems. About two-fifths exhibited multiple lesions, most frequently in the frontoparietal region (46.2%). Half of the patients showed an incomplete ring on post-contrast T1-weighted imaging, with peripheral diffusion-weighted imaging restriction in twenty-one patients. T2-hypointense rims were present in thirteen (56.5%) patients. Brain biopsy was performed in 12 cases (46.1%). Serum aquaporin-4 immunoglobulin was positive in 16.7% of tested (4/24) cases. Serum myelin oligodendrocyte glycoprotein immunoglobulin was negative in all thirteen patients tested. Twenty patients (76.9%) received intravenous corticosteroids for TDL attacks. After the median follow-up period of 48 months (range 6-300), 23.1% experienced CNS-IDD relapses. Median Expanded Disability Status Scale at TDL diagnosis was 4.3 (range 0.0-9.5), and improved to 3.0 (range 0.0-10.0) at the last follow-up. This study suggested that TDL were rare among Thai CNS-IDD patients, frequently presenting as a monophasic condition with a favorable outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.